Ran Reshef

Transplant Surgery

161 Fort Washington Ave
New York, NY 10032

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 151 publications

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

Journal: medRxiv : the preprint server for health sciences

Published: July 29, 2026

A Donor T-Cell Receptor Structural Signature Determines Alloreactive Potential and Predicts Acute Graft-Versus-Host Disease.

A Donor T-Cell Receptor Structural Signature Determines Alloreactive Potential and Predicts Acute Graft-Versus-Host Disease.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

Journal: American journal of hematology

Published: May 29, 2026

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Journal: Blood advances

Published: May 12, 2026

Hematopoietic Cell Transplant Access and Patient Diversity.

Hematopoietic Cell Transplant Access and Patient Diversity.

Journal: JAMA network open

Published: May 05, 2026

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Journal: Haematologica

Published: March 17, 2026

A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma.

A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma.

Journal: bioRxiv : the preprint server for biology

Published: December 19, 2025

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 16, 2025

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Journal: Blood

Published: September 19, 2025

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Journal: Blood

Published: September 19, 2025

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Journal: Transplantation and cellular therapy

Published: July 31, 2025

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

Journal: Blood advances

Published: June 20, 2025

Showing 1-12 of 151

Last Updated: 09/26/2026